Sopan Pharmaceuticals IPO Nepal 2026 Opens Today

23rd March 2026, Kathmandu

The Sopan Pharmaceuticals IPO Nepal 2026 has officially hit the market, marking a major milestone for one of Nepal’s rapidly growing pharmaceutical companies.

Sopan Pharmaceuticals IPO Nepal

Starting today, March 23, 2026 (Chaitra 9, 2082 BS), the company has opened its first phase of the Initial Public Offering. Following the approval from the Securities Board of Nepal (SEBON) granted on Falgun 17, Sopan Pharmaceuticals aims to raise capital to expand its manufacturing capabilities, specifically targeting high-demand medicine segments in the domestic market.

Phase 1: Priority for Foreign-Employed Nepalis

In line with recent regulatory shifts to encourage formal remittance inflows, the Sopan Pharmaceuticals IPO Nepal 2026 begins by prioritizing Nepali citizens working abroad.

• Reserved Shares: 429,000 units (10% of the total public issue).
• Eligibility: Applicants must possess a valid labor permit and a linked Remittance Bachat Khata (Remittance Savings Account) at a Nepalese bank.
• Application Window: The subscription for this category is open from Chaitra 9 to Chaitra 12, 2082.

Total Issue Size and Allocation Structure

The Sopan Pharmaceuticals IPO Nepal 2026 consists of a total of 4.29 million shares (42,90,000 units) at a face value of Rs 100 per share. The company has designated specific quotas to ensure broad-based ownership:

• Foreign-Employed Nepalis: 429,000 shares (Current Phase).
• Mutual Funds: 214,500 shares (5% of the total).
• Company Employees: 171,600 shares (4% of the total).
• General Public: 3,474,900 shares (To be opened in the second phase).

Investment Limits and Process

For investors looking to participate in the Sopan Pharmaceuticals IPO Nepal 2026, the following technical details are essential for a successful application:

• Minimum Application: 10 shares (Requires an investment of Rs 1,000).
• Maximum Application: 11,000 shares (For the foreign-employed category).
• Issue Manager: NMB Capital Limited has been appointed to manage the issuance, allotment, and listing process.
• How to Apply: Eligible investors can apply via the Mero Share portal or through C-ASBA approved banks and financial institutions.

Why Invest in Sopan Pharmaceuticals?

The Sopan Pharmaceuticals IPO Nepal 2026 is gaining traction due to the strategic importance of the healthcare sector in Nepal.

Advertisement

Import Substitution: Nepal currently imports a significant portion of its medicines. Sopan Pharmaceuticals focuses on local production, which aligns with national self-reliance goals.

Infrastructure: The company operates a state-of-the-art facility in Mahalaxmi, Lalitpur, equipped to produce a variety of tablets, capsules, and liquid orals.

Sector Growth: The Nepalese pharmaceutical market is growing at an annual rate of approximately 10-12%, providing a healthy backdrop for new equity listings.

Risk Factors to Consider

While the Sopan Pharmaceuticals IPO Nepal 2026 offers a low entry price of Rs 100, potential investors should perform due diligence regarding:

• Raw Material Costs: Fluctuations in the global price of Active Pharmaceutical Ingredients (APIs).
• Regulatory Changes: Updates in drug pricing policies by the Department of Drug Administration (DDA).
• Competition: Increasing number of domestic manufacturers entering the “generic” medicine space.

Conclusion

The launch of the Sopan Pharmaceuticals IPO Nepal 2026 today provides a prime window for the Nepali diaspora to participate in the country’s industrial growth. With the first phase closing on Chaitra 12, the momentum is expected to build quickly toward the general public offering. For those looking to diversify their portfolio beyond banking and hydropower, this pharmaceutical play represents a modern alternative in the Nepal Stock Exchange (NEPSE) landscape.

For More: Sopan Pharmaceuticals IPO Nepal